Search

everythinglearnresearchcommunity

for

Search:↓

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.

Secukinumab reduces immune activity in hidradenitis suppurativa skin.

ICL is a condition with low CD4+ T cells like AIDS but not caused by HIV, and normal CD4+ T cell counts may vary between men and women.

Methotrexate is not proven effective for inducing remission in ulcerative colitis.

Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.

Triple therapy with clobetasol, hydroxychloroquine, and N-acetylcysteine is recommended for better outcomes in treating lichen planopilaris.

A woman's rare scalp condition worsened after using a specific arthritis medication, suggesting such medications can sometimes trigger or aggravate psoriasis.

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.

Topical tofacitinib shows promise as a future treatment for alopecia areata.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Lenalidomide effectively and safely treats skin symptoms in pediatric lupus, reducing the need for prednisone.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.

Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.

Topical cetirizine may help increase hair count in androgenetic alopecia.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.

Chronic autoimmune urticaria can be managed with specific therapies and requires improved diagnosis and treatment methods.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Tofacitinib may help treat Lichen Planopilaris, but more research is needed.

A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.

A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Tofacitinib significantly improved skin and hair conditions without side effects.